Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%
- Poor long term growth as Operating profit has grown by an annual rate 16.19% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -83.25
2
The company has declared negative results in Dec'2023 after 4 consecutive positive quarters
3
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
HKD 271,179 Million ()
NA (Loss Making)
NA
0.00%
-0.70
2.31%
8.44
Revenue and Profits:
Net Sales:
10,266 Million
(Quarterly Results - Jun 2025)
Net Profit:
736 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.21%
0%
-2.21%
6 Months
15.43%
0%
15.43%
1 Year
78.93%
0%
78.93%
2 Years
83.15%
0%
83.15%
3 Years
60.35%
0%
60.35%
4 Years
6.05%
0%
6.05%
5 Years
43.54%
0%
43.54%
BeiGene Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
79.78%
EBIT Growth (5y)
16.19%
EBIT to Interest (avg)
-83.25
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.45
Sales to Capital Employed (avg)
0.27
Tax Ratio
45.95%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.86
EV to EBIT
-316.93
EV to EBITDA
356.28
EV to Capital Employed
16.05
EV to Sales
6.98
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-5.06%
ROE (Latest)
-4.24%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
10,266.00
8,692.50
18.10%
Operating Profit (PBDIT) excl Other Income
963.90
341.60
182.17%
Interest
94.00
100.80
-6.75%
Exceptional Items
-39.20
0.00
Consolidate Net Profit
736.20
9.90
7,336.36%
Operating Profit Margin (Excl OI)
66.80%
9.90%
5.69%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 18.10% vs -0.87% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 7,336.36% vs 100.84% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
29,731.20
19,249.60
54.45%
Operating Profit (PBDIT) excl Other Income
-3,093.40
-8,768.90
64.72%
Interest
365.90
162.80
124.75%
Exceptional Items
-149.60
177.50
-184.28%
Consolidate Net Profit
-5,031.20
-6,902.80
27.11%
Operating Profit Margin (Excl OI)
-149.10%
-491.20%
34.21%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 54.45% vs 73.62% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 27.11% vs 56.01% in Dec 2023
About BeiGene Ltd. 
BeiGene Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






